Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Show other versions (1)

Introduction - Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain une...

Full description

Bibliographic Details
Main Authors: Claas, Allison Mary (Contributor), Atta, Lyla H. (Contributor), Gordonov, Simon (Contributor), Meyer, Aaron Samuel (Contributor), Lauffenburger, Douglas A (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Springer US, 2018-07-31T15:51:49Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items